Navigating The Journey from Bench to Bedside

Therapeutic antibodies continue to change how we treat human diseases. But antibody discovery and optimization present several challenges and the overwhelming majority of leads that enter pre-clinical testing will fail to navigate the twists and turns on the path to market. Even highly potent and specific candidates can have suboptimal developability profiles and face downstream aggregation, stability, formulation, or manufacturing problems.

Using our best-in-class discovery platform, Twist Biopharma’s antibody experts have discovered and vetted an array of lead antibodies against high-value targets, saving you the trouble of launching your own discovery projects and dealing with these problems internally. These fully human, IgG leads are engineered for developability, de-risked for common downstream liabilities, and built on a partnership aimed at accelerating your journey from bench to bedside.

Erstklassige Therapeutika erfordern eine erstklassige Identifizierungsplattform

Dank unserer einzigartigen, hochwertigen DNA-Schreibplattform können wir diverse Antikörpervarianten mit hoher Präzision bei jeder einzelnen Base entwickeln. Using that as our foundation, we’ve built a best-in-class discovery platform, which served as the starting point for the antibody leads above. Jedes Identifizierungsprojekt erfolgte unter der Leitung unseres internen Expertenteams, das über 50 Jahre Erfahrung mit der therapeutischen Antikörperentwicklung in sich vereint.

Enrich Your Pipeline With Antibodies Discovered and Vetted by Our Experts

Unsere Library of Libraries und die unternehmensinterne Expertise haben die Identifizierung und Auswahl von Leads gegen schwierige Medikamentenziele wie z. B. GLP-1R und ADORA2A ermöglicht. Once selected, each lead goes through our IgG conversion, expression, and purification and our high-throughput developability workflow to assess downstream pre-clinical success.

Erfahrungsbericht

„

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients”.

CLIVE R. WOOD, PH.D Senior Corporate Vice President and Global Head of Discovery Research

Boehringer Ingelheim

Rapidly Reach Clinical Milestones

Our precision DNA writing platform removes downstream development and manufacturing liabilities and unwanted motifs from our libraries. The antibody leads are de-risked through our developability risk assessment, saving you costly and time-consuming rework and giving you the greatest probability of hitting your development and clinical milestones.

Partnering to Accelerate Your Time to Market

Twist Biopharma is your specialty partner for antibody discovery, optimization, and development projects. Our flexible team has led first-in-class discovery and development projects and is equipped to find a broad range of solutions to your unique situation, whether it be additional analysis of our characterized antibody leads, initiating custom library construction, or optimizing leads from other discovery platforms.